ORR in the anti-EGFR group (N = 223)
| Highly sensitive digital PCR | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cobas | Therascreen Pyro | Cutoff 0.1% | Cutoff 1% | ||||||||||||||
| WT | RR WT | MUT | RR MUT | WT | RR WT | MUT | RR MUT | WT | RR WT | MUT | RR MUT | WT | RR WT | MUT | RR MUT | ||
| KRAS (exon 2) | CR | 9 | 42.7 | 1 | 17.4 | 8 | 42.7 | 2 | 20.8 | 9 | 42 | 1 | 34 | 9 | 43.2 | 1 | 24.2 |
| PR | 76 | 3 | 77 | 3 | 65 | 15 | 73 | 7 | |||||||||
| SD | 78 | 9 | 78 | 9 | 72 | 15 | 75 | 12 | |||||||||
| PD | 36 | 10 | 36 | 10 | 30 | 16 | 33 | 13 | |||||||||
| RAS (KRAS ex 2/3/4 + NRAS ex 2/3/4) | CR | 9 | 44.8 | 1 | 27.1 | 8 | 46.3 | 2 | 24.6 | 9 | 47.1 | 1 | 29.9 | 9 | 48.4 | 1 | 22.9 |
| PR | 64 | 15 | 67 | 13 | 55 | 25 | 65 | 15 | |||||||||
| SD | 63 | 24 | 61 | 26 | 49 | 38 | 54 | 33 | |||||||||
| PD | 27 | 19 | 26 | 20 | 23 | 23 | 25 | 21 | |||||||||
| RAS + BRAF | CR | 9 | 45.8 | 1 | 26.9 | 8 | 48.3 | 2 | 25 | 8 | 48.8 | 2 | 29.6 | 8 | 50.4 | 2 | 23.2 |
| PR | 62 | 17 | 63 | 17 | 53 | 27 | 63 | 17 | |||||||||
| SD | 61 | 26 | 57 | 30 | 46 | 41 | 51 | 36 | |||||||||
| PD | 23 | 23 | 19 | 27 | 18 | 28 | 19 | 27 | |||||||||
NOTE: The improvement in response prediction gained by assessing the mutation status of each gene.
Abbreviations: WT, wild-type tumor; MUT, mutated tumor; RR, response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.